Ovaleap is a recombinant follicle-stimulating hormone (rFSH) used in the treatment of infertility in women. It is a bioengineered version of the naturally occurring FSH, a hormone essential for the growth and development of ovarian follicles, which ultimately leads to the production of eggs. Ovaleap is specifically designed to stimulate the ovaries to produce eggs in women who have difficulty conceiving due to problems with ovulation. It is administered through subcutaneous injections and is often used as part of assisted reproductive technologies (ART) such as in vitro fertilization (IVF) to increase the chances of pregnancy. Ovaleap's use is typically supervised by healthcare professionals specialized in reproductive medicine, ensuring the correct dosage and monitoring the patient's response to the treatment.